Navigation Links
FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Date:6/27/2008

enidate or other ingredients in CONCERTA(R); significant anxiety, tension, or agitation; glaucoma; tics, Tourette's syndrome, or family history of Tourette's syndrome; current or past use of monoamine oxidase inhibitor (MAOI); esophagus, stomach, or intestinal narrowing. Children under six years of age should not take CONCERTA(R).

Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if you or your child has had problems with alcohol or drugs; has had any heart problems, heart defects, high blood pressure, or a family history of these problems; has had depression, abnormal thoughts or visions, bipolar disorder, or seizure. Contact your healthcare professional immediately if you or your child: develops abnormal thinking or hallucinations, abnormal or extreme moods and/or excessive activity; or if aggressive behavior or hostility develops or worsens while taking CONCERTA(R).

Stimulants may impair the ability of the patient to operate potentially hazardous machinery or vehicles. Caution should be used accordingly until you are reasonably certain that CONCERTA(R) does not adversely affect your ability to engage in such activities.

The most common adverse reaction (> 5%) reported in children and adolescents was upper abdominal pain. The most common adverse reactions (>10%) reported in adults were dry mouth, nausea, decreased appetite, headache, and insomnia.

Visit http://www.concerta.net/concerta/pages/full.jsp for complete prescribing information.

About McNeil Pediatrics

McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is committed to meeting the needs of pediatric medicine through the development of therapies specifically formulated for children. McNeil Pediatrics markets CONCERTA(R) for the treatment of children, adolescents and adults with ADHD in the United States. McNeil Pediatrics continues
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & DevelopmentL.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
3. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
4. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
5. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
6. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
7. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
8. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
9. Medicare Approves in Home Sleep Apnea Testing
10. 3SBio Inc. Approves Share Repurchase Program
11. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The Americas Inorganic Refrigerants Market report defines ... with analysis and forecast of revenue. , Browse ... Market report, to get an idea of the ... of the segmentation in the Americas inorganic refrigerants ... figures. , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html , Inorganic ...
(Date:10/22/2014)... 22, 2014 Currently offering a ... & D Weighing, Rice Lake, and Ohaus, Pipette.com ... . The Sartorius CPA Semi-Micro Balance is ideal ... precise, and user-friendly laboratory balance. , Sartorius is ... their laboratory balances are well known for their ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Calif., June 23, 2011 Nile Therapeutics, Inc. (OTCQB: ... heart failure patients, today announced that it has completed ... securities consisting of an aggregate of 5,000,000 shares of ... 2,500,000 shares of common stock for aggregate gross proceeds ...
... 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), ... HIV/AIDS vaccines, announced today the opening of a third ... vaccine.  The Los Angeles-based AIDS Research Alliance (ARA) will ... site team: the AIDS Research Consortium of Atlanta and ...
... NEW YORK, June 22, 2011 Veredus Laboratories, a ... partner, STMicroelectronics (NYSE: STM ), today announced ... application that is able to detect 10 to 12 ... Escherichia coli (E. coli) responsible for the ...
Cached Biology Technology:Nile Therapeutics, Inc. Completes $2.5 Million Private Placement 2Nile Therapeutics, Inc. Completes $2.5 Million Private Placement 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 4Veredus Laboratories Develops Lab-on-Chip Solution to Detect and Differentiate Several Food-Borne Pathogens, Including Escherichia coli (E. coli) 2Veredus Laboratories Develops Lab-on-Chip Solution to Detect and Differentiate Several Food-Borne Pathogens, Including Escherichia coli (E. coli) 3Veredus Laboratories Develops Lab-on-Chip Solution to Detect and Differentiate Several Food-Borne Pathogens, Including Escherichia coli (E. coli) 4
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... in female mice to an enzyme activated by the ... resistant to respiratory infections than males. Now, an international ... bacterial pneumonia in female mice is linked to the ... that this enzyme is ultimately activated by the release ... lead by Professor Lester Kobzik at the Harvard University ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3New book about life as seen from physics 2
... from L-1 and Terminates Discussions ... ... ("L-1") (NYSE: ID ), a leading provider of identity solutions ... with Digimarc Corporation ("Digimarc") (Nasdaq: DMRC ). The,proposed transaction values ...
... Calif., June 30, 2008--In a breakthrough scientific study published ... of Sciences , scientists at the Burnham Institute for ... may be linked to Autism. The study demonstrated that ... in neural stem cells had smaller brains, fewer nerve ...
... College of Medicine and her colleagues discovered the first ... the intestines, causing diarrhea. The next step ... through which the enterotoxin interacts to cause diarrhea. ... be straightforward," said the professor of molecular virology and ...
Cached Biology News:Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 2Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 3Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 4Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 5Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 6Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business 7Researchers link early stem cell mutation to autism 2Integrins as receptors give insight into rotavirus and diarrhea 2
Request Info...
Loading Buffer...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Request Info...
Biology Products: